Literature DB >> 32918181

Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.

Robert Power1,2, Cristin Leavy3,2, Carmel Nolan3,2, Niamh White3,2, Roisin Clarke3,2, Karen A Cadoo1,3,2, David James Gallagher1,3,2, Maeve Aine Lowery4,5.   

Abstract

Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are associated with an increased lifetime risk of pancreatic ductal adenocarcinoma (PDAC), and more recently have been associated with increased risk of biliary tract cancers (BTC). This study assessed the prevalence, age and gender distribution of PDAC/BTC cases in families known to carry a BRCA1/2 PV compared to those of the Irish population. A review of all families referred to a national genetics clinic from 09/11/1997 to 01/06/2018 was performed. The BOADICEA algorithm was used to estimate the probability that an untested relative of a known BRCA1/2 PV carrier with PDAC was a carrier. We reviewed 3252 family pedigrees, 1193 contained a proband who underwent testing for BRCA1/2 based on Manchester score ≥ 15. Among 128 BRCA2 PV-positive families, 27 (21%) contained a 1st/2nd/3rd-degree relative with PDAC, while of 116 BRCA1 PV-positive families, 11 (9%) contained a 1st/2nd/3rd-degree relative with PDAC. Within these 38 families, 25 patients with PDAC had ≥ 50% likelihood of being a BRCA1/2 PV carrier. This cohort had a median age at diagnosis of 55 years (range 33-75), with a mean (55 years) lower than 8364 patients with PDAC identified through the National Cancer Registry of Ireland (71 years, p < 0.0001). Six BRCA2 positive (5%) and 2 BRCA1 positive pedigrees (2%) included an individual with BTC; median age at diagnosis was 65 years (range 33-99). PDAC and BTC are prevalent in Irish families harbouring a BRCA2 PV and are associated with early-onset malignancy. This supports current guidelines recommending universal germline testing for PDAC patients.

Entities:  

Keywords:  BRCA1; BRCA2; Biliary tract cancer; Genetic testing; Irish population; Pancreatic cancer

Mesh:

Year:  2020        PMID: 32918181     DOI: 10.1007/s10689-020-00205-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  10 in total

1.  Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series.

Authors:  Terri P McVeigh; Nuala Cody; Cliona Carroll; Marie Duff; Michael Farrell; Lisa Bradley; David Gallagher; Trudi McDevitt; Andrew J Green
Journal:  Cancer Genet       Date:  2017-03-22

2.  Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.

Authors:  Hannah Maynard; Zsofia K Stadler; Michael F Berger; David B Solit; Michele Ly; Maeve A Lowery; Diana Mandelker; Liying Zhang; Emmett Jordan; Imane El Dika; Yelena Kemel; Marc Ladanyi; Mark E Robson; Eileen M O'Reilly; Ghassan K Abou-Alfa
Journal:  Cancer       Date:  2020-02-03       Impact factor: 6.860

Review 3.  Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.

Authors:  Talia Golan; Maria Raitses-Gurevich; Robin K Kelley; Andrea G Bocobo; Ayelet Borgida; Rachna T Shroff; Spring Holter; Steven Gallinger; Daniel H Ahn; Dan Aderka; Jain Apurva; Tanois Bekaii-Saab; Eitan Friedman; Milind Javle
Journal:  Oncologist       Date:  2017-05-09

4.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.

Authors:  Chunling Hu; Steven N Hart; Eric C Polley; Rohan Gnanaolivu; Hermela Shimelis; Kun Y Lee; Jenna Lilyquist; Jie Na; Raymond Moore; Samuel O Antwi; William R Bamlet; Kari G Chaffee; John DiCarlo; Zhong Wu; Raed Samara; Pashtoon M Kasi; Robert R McWilliams; Gloria M Petersen; Fergus J Couch
Journal:  JAMA       Date:  2018-06-19       Impact factor: 56.272

5.  Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.

Authors:  Zsofia K Stadler; Erin Salo-Mullen; Sujata M Patil; M Catherine Pietanza; Joseph Vijai; Emmanouil Saloustros; Nichole A L Hansen; Noah D Kauff; Robert C Kurtz; David P Kelsen; Kenneth Offit; Mark E Robson
Journal:  Cancer       Date:  2011-05-19       Impact factor: 6.860

6.  Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.

Authors:  Daniel H Kim; Beth Crawford; John Ziegler; Mary S Beattie
Journal:  Fam Cancer       Date:  2008-10-15       Impact factor: 2.375

7.  Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.

Authors:  Elena M Stoffel; Shannon E McKernin; Randall Brand; Marcia Canto; Michael Goggins; Cassadie Moravek; Arun Nagarajan; Gloria M Petersen; Diane M Simeone; Matthew Yurgelun; Alok A Khorana
Journal:  J Clin Oncol       Date:  2018-11-20       Impact factor: 44.544

8.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Authors:  Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

9.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

10.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

Authors:  A J Lee; A P Cunningham; K B Kuchenbaecker; N Mavaddat; D F Easton; A C Antoniou
Journal:  Br J Cancer       Date:  2013-12-17       Impact factor: 7.640

  10 in total
  2 in total

Review 1.  Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.

Authors:  Svetlana N Aleksakhina; Evgeny N Imyanitov
Journal:  Int J Mol Sci       Date:  2021-10-10       Impact factor: 5.923

2.  Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.

Authors:  Yunuo Zhang; Heming Wu; Zhikang Yu; Liang Li; Jinhong Zhang; Xinhong Liang; Qingyan Huang
Journal:  BMC Cancer       Date:  2022-08-02       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.